← Browse by Condition
Medical Condition
hematologic malignancy
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, Phase 1, EARLY_Phase 1
ClinicalMetric tracks all active clinical trials for hematologic malignancy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — hematologic malignancy Clinical Trials
How many clinical trials are currently recruiting for hematologic malignancy?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for hematologic malignancy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematologic malignancy?
hematologic malignancy research spans Phase 1 (3 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematologic malignancy clinical trial?
Eligibility criteria for hematologic malignancy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07006506 Phase 2
Recruiting
Enrollment
46 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06472089
Recruiting
Enrollment
800 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT06252870 Phase 2
Recruiting
Enrollment
82 pts
Location
France
Sponsor
Nantes University Hospital
NCT06484816 Phase 1
Recruiting
Enrollment
90 pts
Location
China
Sponsor
Shenzhen TargetRx Co., Ltd.
NCT05708716
Recruiting
Enrollment
80 pts
Location
United States
Sponsor
University of Alabama at Birmi...
NCT07014449 Phase 1
Recruiting
Enrollment
18 pts
Location
China
Sponsor
Hangzhou Weben Pharma Co., Ltd
NCT06731504 EARLY_Phase 1
Recruiting
Enrollment
10 pts
Location
United States
Sponsor
Duke University
NCT06416761
Recruiting
Enrollment
10,000 pts
Location
Italy
Sponsor
Ospedale San Raffaele
Related Conditions
graft versus host disease (2) bone marrow transplant complications (2) graft vs host disease (1) non small cell lung cancer (1) advanced solid tumor (1) cognitive impairment (1) aml acute myelogenous leukemia (1) relapsed acute myelogenous leukemia (1) refractory acute myeloid leukemia (1) c myc (1) adult acute myeloid leukemia (1) aki (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology